CXCL8 and rheumatoid arthritis: This molecular alteration results in decreased production of IL-6, interleukin-8 (IL-8), matrix metalloproteinase-1 (MMP1), and matrix metalloproteinase-13 (MMP13) in human RA SF, underscoring the pivotal regulatory role of miR-17 in inflammatory and degradative pathways in RA (63).